New Research Sheds Light on Factors Influencing Medical Scheme Enrolment Decisions

By HEOR Staff Writer

July 24, 2023

The Council for Medical Schemes recently published an insightful study in the American Journal of Biomedical Science and Research titled ‘Profiling Dependants Joining Medical Schemes: An Analysis of Factors Influencing Enrolment Decisions.’

The study provides a fresh perspective in the ongoing debate between ‘medical aids’ and ‘cheap medical aid.’ From 2017 to 2021, an average of 1.1 million new dependants joined medical schemes each year, with newborns making up 23% and children under five accounting for 35%.

The authors suggest that by understanding enrolment decisions, medical schemes can tailor their strategies to the specific needs of dependants, potentially leading to higher enrolment rates and improved healthcare outcomes.

Enrolment in a medical scheme is a complex process influenced by multiple factors, including affordability, age, and healthcare needs.

Interestingly, in 2019, medical schemes collectively saw a high number of new dependants join the scheme at 1.3 million. However, in 2021, this number dropped to 622,000, likely due to the economic impact of COVID-19.

Closed schemes tend to enrol more new dependants below the age of 5, while open schemes typically enrol more beneficiaries aged 60 years.

The study also revealed that costs, availability of cost-sharing mechanisms, and financial incentives influence dependants’ decision to enrol in medical schemes.

To expand health insurance coverage, interventions should prioritize the healthcare needs of children and the elderly.

Reference url

Recent Posts

Expansion of Community Health Programs by Novartis to Tackle Global Health Disparities

By João L. Carapinha

April 9, 2026

Novartis’ ambitious scale-up of community health programs aims to close critical gaps in cardiovascular and cancer care. Announced on April 9, 2026, the initiative will expand these community health programs from 11 to more than 30 countries by 2030, including five major U.S. cities, with a stron...
Enhancing Obesity Treatment Pricing in South Africa Through Competitive Strategies

By João L. Carapinha

April 2, 2026

Novo Nordisk has cut the price of Wegovy for the second time in South Africa, making obesity treatment pricing South Africa a key focus for improved patient access. The latest reductions, announced on 25 March 2026, lower the lowest injectable dose from 3,090 rand to 1,873 rand and the highest do...
South Africa Health Reform: Revitalizing the Crisis-Stricken Sector

By João L. Carapinha

March 26, 2026

South Africa health reform is urgently needed to reverse the deepening crisis in the country’s public and private health sectors. Sustained real-term declines in public per-capita spending, massive provincial debt, critical staff shortages, and uncontrolled private-sector cost escalation are coll...